- Home
- NBTX vs CDXS Comparison
NBTX vs CDXS Comparison
Compare NBTX & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- CDXS
- Stock Information
- Founded
- NBTX 2003
- CDXS 2002
- Country
- NBTX France
- CDXS United States
- Employees
- NBTX N/A
- CDXS N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- CDXS Major Chemicals
- Sector
- NBTX Health Care
- CDXS Industrials
- Exchange
- NBTX Nasdaq
- CDXS Nasdaq
- Market Cap
- NBTX 167.8M
- CDXS 201.3M
- IPO Year
- NBTX 2020
- CDXS 2010
- Fundamental
- Price
- NBTX $4.10
- CDXS $2.30
- Analyst Decision
- NBTX Strong Buy
- CDXS Buy
- Analyst Count
- NBTX 1
- CDXS 2
- Target Price
- NBTX $8.00
- CDXS $11.00
- AVG Volume (30 Days)
- NBTX 11.5K
- CDXS 1.0M
- Earning Date
- NBTX 04-02-2025
- CDXS 05-14-2025
- Dividend Yield
- NBTX N/A
- CDXS N/A
- EPS Growth
- NBTX N/A
- CDXS N/A
- EPS
- NBTX N/A
- CDXS N/A
- Revenue
- NBTX N/A
- CDXS $49,815,000.00
- Revenue This Year
- NBTX N/A
- CDXS $2.41
- Revenue Next Year
- NBTX $221.06
- CDXS $34.28
- P/E Ratio
- NBTX N/A
- CDXS N/A
- Revenue Growth
- NBTX N/A
- CDXS N/A
- 52 Week Low
- NBTX $2.76
- CDXS $1.90
- 52 Week High
- NBTX $7.29
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- NBTX 64.63
- CDXS 44.61
- Support Level
- NBTX $3.64
- CDXS $2.30
- Resistance Level
- NBTX $4.20
- CDXS $2.56
- Average True Range (ATR)
- NBTX 0.16
- CDXS 0.20
- MACD
- NBTX 0.04
- CDXS -0.01
- Stochastic Oscillator
- NBTX 88.51
- CDXS 46.67
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.